upgrad ow new product drive top-lin
acceler upsid street estim
head abbott fundament appear solid end market perform
well organ growth reach back multipl new product
launch includ us launch freestyl libr glucos monitor
system alin famili next-gener core lab system heartmat
left ventricular assist system confirm rx implant cardiac monitor icm
compet mdt linq mri-compat icd crt-d close
competit gap strong top line year deal accret st
jude plu year aler turn organ sale growth
ep growth potenti kick come compani abil
access ou cash post tax reform accret debt paydown
see upsid potenti street estim top
bottom line upgrad abbott share neutral overweight
rais y/e price target valu share equal blend
ep ebitda
multipl new product launch excit libr
like room upsid freestyl libr compani innov
glucos monitor system almost sale way
model libr launch us decemb
best case label fingerstick replac similar albeit
calibr highli aggress market strategi forecast us libr
sale see upsid abbott secur either
commerci reimburs earlier expect medicar reimburs
vs assumpt pediatr label prior
new cardiovascular product turn abbott franchis
headwind tailwind late septemb abbott fda approv
mri-compat label ellips secur similar label
crt-d day back approv expect sale
grow vs declin electrophysiolog abbott
launch confirm rx icm compet directli medtron linq
annual us sale unlik linq confirm rx bluetooth-en
allow patient use smartphon monitor upload data
physician model abbott global icm sale grow
abbott benefit well
late august approv subsequ launch heartmat us
expect kick-start market drive double-digit growth
page analyst certif import disclosur
 morgan seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report singl
factor make invest decis
worth spend minut estim mani street appear
mis-model sale abbott starter forecast sale
report organ pro-forma aler vs street rang
view new product launch
forecast correctli big discrep estim street
diabet electrophysiolog heart failur
ahead nutrit part could due differ fx model
report growth fx-neutral growth model diabet heart
failur electrophysiolog aggreg sale grow double-digit cagr
end decad
offset matur price challeng busi
coronari vascular cautiou vascular
boston continu gain de share rhythm manag aler wildcard
view pro-forma histor unknown believ well clariti
front sometim januari ahead earn investor expect aler
dilut abbott growth eas comparison icd
chines nutrit abbott abl deliv pro-forma growth
year st jude aler accret drive growth bottom line weve
note abbott expos potenti price cut china australia japan
part stent franchis worst-cas scenario estim
would ep word manag
upgrad abbott share neutral overweight rais
price target valu share ep
ebitda modest premium vs peer trade today ntm ep
ebitda feel appropri given abbott top- bottom-lin growth
outlook upsid potenti see street estim come year
invest thesi valuat risk
head fundament abbott appear solid end market perform
well organ growth reach back multipl new product
launch includ us launch freestyl libr glucos monitor
system alin famili next-gener core lab system heartmat
left ventricular assist system confirm rx implant cardiac monitor icm
compet mdt linq mri compat icd crt-d close
competit gap strong top-lin year deal accret st jude
plu year aler turn organ sale growth ep
growth potenti kick come compani abil access
ou cash post tax reform accret debt paydown see upsid
street estim top bottom line upgrad abbott
share neutral overweight rais y/e price target
price target valu share ep
ebitda modest premium vs peer trade today ntm ep
ebitda feel appropri given abbott top bottom-lin growth
outlook upsid potenti see street estim come year
risk rate price
downsid risk rate includ abbott macro exposur emerg market
poor integr failur stabil aler busi potenti pipelin
new product launch disappoint
abbott laboratori summari financi
cash equival
flow oper activ
o/w chang work capit
flow invest activ
sale
flow financ activ
net chang cash
adj free cash flow firm
compani report morgan estim
note million except per-shar data fiscal year end dec o/w
analyst certif research analyst denot ac cover report certifi multipl research
analyst primarili respons report research analyst denot ac cover within document
individu certifi respect secur issuer research analyst cover research view
express report accur reflect person view subject secur issuer part
research analyst compens directli indirectli relat specif recommend view
express research analyst report korea-bas research analyst list front cover also certifi per
kofia requir analysi made good faith view reflect opinion without undu influenc
